The sole question on appeal was whether it would have been obvious to make zolmitriptan into a nasal spray. The Federal Circuit agreed with the district court that the prior art taught away from formulating zolmitriptan for intranasal administration.
The post Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious appeared first on IPWatchdog.com | Patents & Patent Law.
Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- NetSoc Appeals to SCOTUS, Claiming Improper Analysis of Social Network Patent Nixed Under 101
- The View from the Court’s 2 Live Crew: Examining the Thomas/Alito Dissent in Google v. Oracle
- Tillis, Michel and Iancu Back Ericsson in Heated International FRAND Dispute with Samsung
- The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic – Part I
- The Upshot of Google v. Oracle: An Absurd Ruling Will Lead to Absurd Results
Recent Posts
- NetSoc Appeals to SCOTUS, Claiming Improper Analysis of Social Network Patent Nixed Under 101
- The View from the Court’s 2 Live Crew: Examining the Thomas/Alito Dissent in Google v. Oracle
- Tillis, Michel and Iancu Back Ericsson in Heated International FRAND Dispute with Samsung
- The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic – Part I
- The Upshot of Google v. Oracle: An Absurd Ruling Will Lead to Absurd Results